In a significant development for medical cannabis in the UK, Celadon Pharmaceuticals Plc was proud to be featured on Sky News. Celadon has initiated the first MHRA and NHS REC approved trial of its kind, targeting 5,000 patients with chronic pain. This follows the legalisation of medical cannabis in 2018, yet its absence in NHS prescriptions due to a lack of funded clinical trials.
Celadon stands out in its approach, cultivating cannabis in controlled environments to ensure precise levels of active compounds. This trial, approved by the MHRA and the NHS Research Ethics Committee, aims to provide robust evidence of cannabis's efficacy and safety, potentially altering the current medical landscape.
#ChronicPain #NHS #medicine #cannabisindustry #CEL #lse
At Celadon Pharmaceuticals, patients are at the heart of everything we do.
Our mission is focused on improving the quality of life for patients most in need by developing breakthrough cannabis-based medicines.
#PharmaceuticalInnovation#LifeSciences#HealthcareInnovation#GMP
CEL D9-27 has been developed as a pessary designed to support women living with endometriosis, with over 12 months of clinical data and development using the EHP-30 Gold Standard Framework to help focus on patient centred outcomes that matter most.
#Endometriosis#WomensHealth
Many people have never heard of the Endocannabinoid System, despite it being one of the body’s most important regulatory systems. Education around the ECS is still limited, which is why increasing awareness and understanding is so important.
#EndocannabinoidSystem#pharma
At Celadon Pharmaceuticals, innovation starts with listening to patients. Over the past 18+ months, our team has been dedicated to the development of CEL D9-27 a pessary formulation designed to support women living with endometriosis and chronic pelvic discomfort.
Although nearly three-quarters of the Scottish public are misinformed about the legal status of medicinal cannabis, support for it in Scotland is higher than in most other parts of the United Kingdom.
https://t.co/hhMNeOCtZe
#CEL#Medical#Cannabis#CeladonPharmaceuticals
UK adults remain confused about the legal status and availability of medical cannabis, despite it being legalised in 2018, a new survey has revealed.
https://t.co/ONNKEuF7UM
#CEL#Medical#Cannabis#CeladonPharmaceuticals
Celadon Pharmaceuticals Plc would like to address a number of enquiries received from shareholders regarding the RNS announcement this morning (24th March 2025), in which the Company proposed to seek shareholder approval to delist from AIM.
𝟭. 𝗬𝗼𝘂𝗿 𝗦𝗵𝗮𝗿𝗲𝘀 𝗥𝗲𝗺𝗮𝗶𝗻 𝗬𝗼𝘂𝗿𝘀
First and foremost, shareholders have not lost their shares. All existing shareholdings remain valid, and in the event of a de-listing, every current shareholder will continue to hold the same number of shares in Celadon. The Company is not cancelling or otherwise eliminating any shareholdings.
𝟮. 𝗦𝗵𝗮𝗿𝗲𝗵𝗼𝗹𝗱𝗲𝗿 𝗩𝗼𝘁𝗲 𝗼𝗻 𝗗𝗲𝗹𝗶𝘀𝘁𝗶𝗻𝗴
A date will be proposed for a General Meeting at which all shareholders will have the opportunity to vote on whether Celadon should remain on the AIM market or cancel its listing. The outcome will be determined by the collective vote of shareholders in accordance with the Company’s articles of association and relevant AIM rules.
𝟯. 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗗𝗲𝗹𝗶𝘀𝘁𝗶𝗻𝗴
If shareholders approve the delisting, Celadon will become a privately held company and its shares will no longer trade on AIM. However, your shareholding in Celadon remains unchanged; the only difference is that Celadon would no longer be listed on the AIM market.
𝟰. 𝗠𝗮𝘁𝗰𝗵𝗲𝗱 𝗕𝗮𝗿𝗴𝗮𝗶𝗻 𝗙𝗮𝗰𝗶𝗹𝗶𝘁𝘆
In the event of a delisting, Celadon intends to provide a Matched Bargain Facility to enable shareholders to continue trading their shares. The facility is anticipated to be administered by J P Jenkins, a well-established platform that allows trades in unlisted companies. Should the delisting proceed, existing shareholders will automatically be able to hold and, if desired, trade their shares through J P Jenkins, while the Company simultaneously explores a potential US listing to further enhance capital access and global growth opportunities.
𝟱. 𝗥𝗲𝗮𝘀𝗼𝗻𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗣𝗿𝗼𝗽𝗼𝘀𝗲𝗱 𝗗𝗲𝗹𝗶𝘀𝘁𝗶𝗻𝗴
James Short, Chief Executive Officer and a significant shareholder in the Company, believes that withdrawing from the AIM market would:
• Substantially reduce the Company’s operational costs associated with maintaining a public listing.
• Facilitate easier access to further capital, on terms the Company believes will be more favourable as a private entity.
Finally, we would like to reassure all shareholders that the normal day-to-day operations and strategic direction of Celadon will continue unaffected. Whether listed or unlisted, the Company remains committed to executing its business plans, maintaining our research and development initiatives, and delivering value for our shareholders. Our leadership team and staff remain focused on driving growth and pursuing the opportunities that lie ahead.
#RNS #RNSUPDATE #CEL #CELADON #BUSINESSUPDATE #NASDAQ #NYSE #LSE #AIM
Celadon continues to engage closely with all creditors and stakeholders to ensure sufficient liquidity through April 2025, with the new facility expected to support operations into Q3 2025.
#CEL#Medical#Cannabis#CeladonPharmaceuticals
In 2024, the UK’s total medical cannabis flower imports more than doubled, rising from nearly 7 tonnes in 2023 to over 15 tonnes in 2024.
For the year to date, the UK has imported just over 2 tonnes, nearly half of which was sourced from Spain.
https://t.co/KETbJOhNTw
#CEL #Medical #Cannabis #CeladonPharmaceuticals #Biotech #Healthcare #ChronicPain
A survey has revealed that 84% of UK doctors would be willing to prescribe medical cannabis to manage chronic pain if it were part of the NHS toolkit.
The research, commissioned by medical cannabis clinic Alternaleaf, comes as experts warn that the number of chronic pain patients in the UK is expected to rise by 1.9 million by 2040. The survey also found that 78% of doctors believe opioids are currently prescribed too frequently for pain relief in the UK, with one in three (29%) concerned that the NHS is not prepared for the projected increase in chronic pain patients.
https://t.co/P9itmZtMpm
#CEL #Medical #Cannabis #CeladonPharmaceuticals #Biotech #Healthcare #ChronicPain
Record numbers of Scots are paying for medical cannabis as NHS waiting lists leave them struggling to get conventional treatment.
An unprecedented 3,440 Scots now have private prescriptions for the drug – mostly patients suffering from common conditions such as depression, anxiety, or chronic pain.
https://t.co/ODNNpQ6HQi
#CEL #Medical #Cannabis #CeladonPharmaceuticals #Biotech #Healthcare #ChronicPain
Celadon is one of the first UK companies to be awarded licences by UK regulators and MHRA to cultivate and manufacture high-THC medicinal cannabis. The company operates in a highly regulated environment and as such is committed to the following standards and licences:
Controlled Drugs licence from UK regulators:
This is the licence required for Celadon to cultivate, store and manufacture pharmaceutical cannabis at its facility.
Good Agricultural and Collection Practices (GACP):
This is the certification required to cultivate cannabis flowers for wholesale distribution or for use in pharmaceutical manufacturing.
Celadon’s indoor, hydroponic cultivation technology enables pharmaceutical level consistency and repeatability, to the tightest tolerance, in order to produce a pharmaceutical-grade GMP product; this is much harder to achieve using conventional greenhouse cultivation approaches.
Good Manufacturing Practices (GMP):
This is the gold-standard pharmaceutical certification granted by the Medicines and Healthcare Products Regulatory Agency (MHRA) required to manufacture medicines for human consumption.
Celadon is one of a small number of companies globally of its kind to be awarded GMP certification for a natural high-THC API.
This milestone licence will enable Celadon to sell its high-THC API into the manufacturing market for the development of pharmaceutical medicines, subject to an update to its existing licence by UK regulators, as well as enable Celadon to use its API in the development of its own finished medicines for both clinical trials and selling under the “specials” framework in the UK. It also enables Celadon to partner with world-leading pharmaceutical companies who wish to manufacture cannabinoid-based medicines, whether THC, CBD or other cannabinoids.
Celadon’s proprietary API manufacturing process is led by its in-house Production and Quality teams to ensure the highest quality pharmaceutical product.
#CEL #Medical #Cannabis #CeladonPharmaceuticals #Biotech #Healthcare #ChronicPain
While NHS progress remains stagnant, private cannabis clinics such as Releaf, are seeing growing numbers of patients report positive effects of cannabis-based treatments for a wide range of conditions.
https://t.co/55ucTYn35x
#CEL#Medical#Cannabis#CeladonPharmaceuticals #Innovation
The three year secured committed credit facility with a Swiss-based individual lender is in addition to the existing unsecured £7.0m committed credit facility.
As part of entering into the Facility the Company obtained a waiver from the Existing Facility provider to prevent any funds drawn down under the Facility being used to repay the Existing Facility. In return the Company committed to the Existing Facility provider that the Company's total indebtedness cannot exceed £7.0million for the term of the Existing Facility.
#CEL #Medical #Cannabis #CeladonPharmaceuticals #Innovation
"We are pleased to have secured funding through the Facility at such an important time in the Company's growth journey. This Facility will support the growth in our operations to meet the growing interest in Celadon's product.
"The additional flexibility that this brings to the Group will enable us to support supply to our existing customers."
#CEL #Medical #Cannabis #CeladonPharmaceuticals #Innovation
Celadon Pharmaceuticals Plc - New Committed Credit Facility
Celadon Pharmaceuticals Plc announces that it has entered into a £1.95 million, three year secured committed credit facility with a Swiss-based individual lender.
https://t.co/zA2eKDjp2Y
#CEL#Medical#Cannabis